Moderna

The groundhog is about to tell us how much longer winter might last. At the same time, events in February could give investors an idea how much longer COVID-19 might keep the economy’s emergency brake pressed to the floor. Will earnings and data begin to show more signs of recovery from the...

2020 was saved thanks to Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) whose vaccines against COVID-19 helped us see the light at the end of the pandemic tunnel. But unlike Pfizer with its rich long history in vaccines, Moderna became a household name only after its mRNA-1273...

First of all, welcome back. Here’s hoping you had a great holiday season and feel ready for another exciting year of these fascinating financial markets. The calendar is new, but the same old pandemic continues to cloud the economic outlook and, let’s face it, life as a whole. Last year...

The lame-duck Congress has a bill. A coronavirus relief bill that is. Lawmakers passed an $892 billion stimulus package that includes funds for small businesses, bolstered unemployment benefits, $600 direct payments for most Americans—  including dependent children—and a bailout...

The Past Week, In A Nutshell What Happened: Despite a volatile week, U.S. index futures managed to establish new all-time highs. Remember This: “In the longer term, the good news is that vaccines are now rolling out increasingly quickly,” said Brad McMillan, chief investment officer at...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The week's bullish calls included an oil supermajor and cloud stocks. A top electric vehicle maker and a COVID-19 vaccine play were among the bearish calls. The U.S. approval of a second COVID-19...

It’s the final day of the final full week of the year, and the race is on for Congress to reach a stimulus ahead of Christmas.  Even before that, they have to find a way to keep the lights on in Washington by the end of today. Unless negotiators make a lot of progress very fast or move...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The week's bullish calls included the iPhone maker and aerospace and apparel leaders. A top electric vehicle maker and a COVID-19 vaccine play were among the more bearish calls. Though the year is in...

While the pandemic is raging for the second time this year, pharmaceutical giants are giving the world hope of ending the COVID-19 nightmare. On Monday, Moderna Inc (NASDAQ: MRNA) said it will apply for U.S. and European emergency authorization of its vaccine candidate as late-stage study results...

Now that November has come to a close, the holidays and a much-needed break seem that much closer. Before fully diving into the final 23 trading days of 2020, however, take a look at where U.S. equities ended the month. Despite the major indices, excluding the Nasdaq-100, closing Monday in the red...

After the whipsaw year we’ve had, many investors would probably be just fine with a dull December. There are signs they might get it, with many of the rough spots receding. The election was almost a month ago, earnings season is practically over, and, perhaps best of all, vaccines appear on...

The Past Week, In A Nutshell What Happened: After the abrupt rotation into value and small-cap stocks on the procurement COVID-19 coronavirus vaccines and news of further lockdowns, broad-market indices ended flat-to-down. Remember This: “Historically the overall retail investor sentiment or...

The cover story from this weekend's Barron's discusses why now is the time for investors to start shopping abroad. Other featured articles examine emerging market value stocks worth a look, alternative ways to invest in stocks with lofty share prices and the post-vaccine sweet spot for...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The bullish calls this past week included a struggling retailer and a Warren Buffett pick. A COVID-19 vaccine frontrunner and a pot stock were featured among the week's bearish calls. Investors and...